Phaseline

Companies › MeiraGTx

MeiraGTx: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Neurology, Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AAV2-hAQP1
AAV2-delivered aquaporin-1 gene therapy
AQP1Phase 2Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid GlandsJun 2027
AAV-GAD
Glutamic acid decarboxylase (GAD) gene transfer via adeno-associated virus
GAD1Phase 1Parkinson's DiseaseOct 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05926765AAV2-hAQP1Phase 2Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid GlandsOncologyJun 2027
NCT05894343AAV-GADPhase 1Parkinson's DiseaseNeurologyOct 2029

From the company's SEC filings

Cash of $143m on 2026-06-30; operating cash outflow about $42m a year; runway about 41 months at that burn, to Nov 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

GAD1 (1) AQP1 (1)

Companies with the same targets

RiboX Therapeutics

Companies built like this

Rapa Therapeutics Ever Supreme Bio Technology Hrain Biotechnology Marzieh Ebrahimi Beijing Yongtai Ruike Biotechnology Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.